Drug Type Small molecule drug |
Synonyms ME 3183, ME-3183 |
Target |
Action inhibitors |
Mechanism PDE4 inhibitors(Phosphodieterase 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePending |
First Approval Date- |
Regulation- |
Molecular FormulaC19H20F2N4O3S |
InChIKeyFJBDQIRRDKSQTK-UHFFFAOYSA-N |
CAS Registry2231329-25-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic large plaque psoriasis | Phase 2 | United States | 24 Mar 2022 | |
Chronic large plaque psoriasis | Phase 2 | Canada | 24 Mar 2022 |
Phase 2 | 132 | (ME3183 Dose 1, BID) | syupfkjyue = vtppumqskm lqmuifyhha (qurzagzmzd, aespkzbqyz - zphbibyofq) View more | - | 27 Jun 2024 | ||
(ME3183 Dose 2, QD) | syupfkjyue = ejaitkkrhm lqmuifyhha (qurzagzmzd, awbriroanw - jpwtwisouy) View more | ||||||
Phase 2 | 132 | odydjkxcxq(gnrkalueke) = dfajtvevsg hxvteqzpgg (pjhtbpyzbj ) | Positive | 11 Oct 2023 | |||
odydjkxcxq(gnrkalueke) = xutngyhbmu hxvteqzpgg (pjhtbpyzbj ) |